These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 28600647)
1. Hybrid Goorts B; Vöö S; van Nijnatten TJA; Kooreman LFS; de Boer M; Keymeulen KBMI; Aarnoutse R; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1796-1805. PubMed ID: 28600647 [TBL] [Abstract][Full Text] [Related]
2. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522 [TBL] [Abstract][Full Text] [Related]
3. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer. Ng SP; David S; Alamgeer M; Ganju V Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging. Botsikas D; Kalovidouri A; Becker M; Copercini M; Djema DA; Bodmer A; Monnier S; Becker CD; Montet X; Delattre BM; Ratib O; Garibotto V; Tabouret-Viaud C Eur Radiol; 2016 Jul; 26(7):2297-307. PubMed ID: 26477029 [TBL] [Abstract][Full Text] [Related]
7. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
9. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer. Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435 [TBL] [Abstract][Full Text] [Related]
10. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients. Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385 [TBL] [Abstract][Full Text] [Related]
11. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316 [TBL] [Abstract][Full Text] [Related]
12. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Zhang X; Wu F; Han P Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT. You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204 [TBL] [Abstract][Full Text] [Related]
15. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients. Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417 [TBL] [Abstract][Full Text] [Related]
16. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381 [TBL] [Abstract][Full Text] [Related]
17. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792 [TBL] [Abstract][Full Text] [Related]
18. Salminen A; Jambor I; Merisaari H; Ettala O; Virtanen J; Koskinen I; Veskimae E; Sairanen J; Taimen P; Kemppainen J; Minn H; Boström PJ Cancer Imaging; 2018 Aug; 18(1):25. PubMed ID: 30068379 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study. Taneja S; Jena A; Goel R; Sarin R; Kaul S Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709 [TBL] [Abstract][Full Text] [Related]
20. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. Liu Q; Wang C; Li P; Liu J; Huang G; Song S Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]